Public Health Seminar Series:

Why Aren’t All Cancers The Same? by Dr. Paul C. Boutros, PhD, MBA

Monday, February 11, 2019 12:00pm - 1:00pm Calit2 Auditorium OCW Video Archive
Seminar Abstract

Human cancers are remarkably variable in their initial presentation. They can arise in almost every organ of the body, at almost any age. Even within a single tumor type, they vary dramatically in morphological characteristics, like their size, location within an organ and cellular structure. These larger changes are reflected in, and presumably are partially driven by, differences in the specific somatic mutational characteristics of tumours. Indeed, while individual tumors can harbor tens to hundreds of thousands of mutations, the median number shared by any pair of cancers is zero. These morphological and molecular heterogeneities are mirrored by a remarkable heterogeneity in clinical outcomes. There thus remains an urgent need to understand which tumors are highly aggressive, and which are not, so that therapies can be tailored to individual patients and both over- and under-treatment prevented. We systematically evaluated of the origins of differential tumour aggressivity. Initially using prostate cancer as a model tumor type, we quantified the relative contributions of somatic mutational features, epigenomic features, transcriptomic features and proteomic features. Ultimately we discover that aggressivity is a complex function of all these, and is driven not only by those mutations present at diagnosis, but also by the evolutionary trajectory upon which the tumor is progressing. Finally, we evaluate why evolutionary trajectories differ within and between a broad range of cancer types, and offer suggestions for the derivation of evolutionarily-aware biomarkers.

Speaker Biography - Dr. Paul C. Boutros, PhD, MBA

Dr. Paul C. Boutros, PhD, MBA
Dr. Paul C. Boutros, PhD, MBA Director, Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director Cancer Informatics, Institute for Precision Health, UCLA
Dr. Paul Boutros pursued his undergraduate education at the University of Waterloo in Chemistry. During the co-op portion of his degree he worked for a wide range of organizations, including the Federal Government, a water-purification company and Petro-Canada. But he found his true calling during a work-term spent at Michigan State University developing computer models of how cells respond to drugs and toxins. Dr. Boutros’ undergraduate thesis extended this work to focus on modeling DNA damage, and was awarded First Place in the National Undergraduate Chemistry Conference. In 2004, Paul started his PhD at the Ontario Cancer Institute, in Toronto. During his studies he received several awards, including the CIHR/Next Generation First Prize and the Invitrogen Canada Young Investigator Silver Award. After publishing 27 peer-reviewed papers over four years, Paul was awarded his PhD in 2008 for his development of novel biomarkers for predicting cancer severity. In 2008, Paul started his independent research career at the Ontario Institute for Cancer Research, as Principal Investigator in Informatics & Biocomputing, and Assistant Professor in the Departments of Pharmacology & Toxicology and Medical Biophysics at the University of Toronto. He is a Prostate Cancer Canada Rising Star in Prostate Cancer Research, a Terry Fox New Investigator Award recipient, a University of Waterloo Young Alumni Award winner and recipient of the Early Career Graduate Student Teaching Award. In 2016 he received his MBA from the University of Toronto, and in 2018 Paul was awarded the Dorval Prize by the Canadian Cancer Society, recognizing the best early career investigator nationally. In 2018, Paul relocated to the University of California, Los Angeles, taking on leadership roles at the Jonsson Comprehensive Cancer Centre and the Institute for Precision Health. As a Professor in the Departments of Human Genetics and Urology, Paul’s research focuses on personalizing therapy for cancer by developing novel statistical methodologies. He leads the ICGC-TCGA DREAM Somatic Mutation Calling Challenge that is setting global standards for analyzing cancer genomic data, and drives programs in cancer genomics, data science and biomarker translation.

Seminars are FREE and open to the public. If you can not attend, Videotapes of Public Health seminars are archived through the UC Irvine OpenCourseWare program - please visit OpenCourseWare:

For updates, please refer to this web page:

Copyright © 2020 The Regents of the University of California. All rights reserved.